Compare GGG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGG | UTHR |
|---|---|---|
| Founded | 1926 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | GGG | UTHR |
|---|---|---|
| Price | $83.39 | $489.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $94.00 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 883.0K | 424.3K |
| Earning Date | 01-26-2026 | 10-29-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | 3.48 | ★ 16.08 |
| EPS | 2.93 | ★ 26.38 |
| Revenue | $2,192,120,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $6.75 | $13.64 |
| Revenue Next Year | $4.83 | $5.78 |
| P/E Ratio | $28.50 | ★ $18.55 |
| Revenue Growth | 2.85 | ★ 13.50 |
| 52 Week Low | $72.06 | $266.98 |
| 52 Week High | $91.00 | $492.62 |
| Indicator | GGG | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 68.10 |
| Support Level | $81.32 | $470.13 |
| Resistance Level | $83.16 | $492.62 |
| Average True Range (ATR) | 1.46 | 10.72 |
| MACD | 0.34 | -0.53 |
| Stochastic Oscillator | 84.01 | 89.55 |
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.